the amount of blood 0 surgical patients can donate and store before surgery can be increased by the new genetically engineered drug , epo . epo , or erythropoietin , is a protein 0 the human body makes to stimulate the growth of red blood cells . a genetically engineered version of the human protein developed by amgen corp. of thousand oaks , calif. , recently has been marketed by the ortho pharmaceuticals division of johnson & johnson . a competing version of epo is being developed by genetics institute inc. in cambridge , mass . the drug is being used primarily to treat anemias . a new experiment , reported in this week 's new england journal of medicine , involved giving injections of amgen 's epo to 23 patients who wanted to store units of their own blood . the patients began receiving epo injections about a month before their scheduled surgery . they then began donating blood twice a week , receiving an epo injection each time . if tests indicated a low number of red cells , blood was n't taken . the epo-treated patients donated an average of 5.4 units of blood each compared with only 4.1 units donated by a similar group of surgical patients who received a placebo injection . the volume of red cells donated by the epo-treated patients was 41 % higher per donor , the research team representing a number of hospitals and blood banks reported 0 .